JP2006507013A5 - - Google Patents

Download PDF

Info

Publication number
JP2006507013A5
JP2006507013A5 JP2005506130A JP2005506130A JP2006507013A5 JP 2006507013 A5 JP2006507013 A5 JP 2006507013A5 JP 2005506130 A JP2005506130 A JP 2005506130A JP 2005506130 A JP2005506130 A JP 2005506130A JP 2006507013 A5 JP2006507013 A5 JP 2006507013A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005506130A
Other languages
English (en)
Japanese (ja)
Other versions
JP4585968B2 (ja
JP2006507013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015046 external-priority patent/WO2004014292A2/en
Publication of JP2006507013A publication Critical patent/JP2006507013A/ja
Publication of JP2006507013A5 publication Critical patent/JP2006507013A5/ja
Application granted granted Critical
Publication of JP4585968B2 publication Critical patent/JP4585968B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005506130A 2002-05-10 2003-05-12 ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法 Expired - Fee Related JP4585968B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37936802P 2002-05-10 2002-05-10
US41820402P 2002-10-14 2002-10-14
US46035803P 2003-04-03 2003-04-03
PCT/US2003/015046 WO2004014292A2 (en) 2002-05-10 2003-05-12 EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

Publications (3)

Publication Number Publication Date
JP2006507013A JP2006507013A (ja) 2006-03-02
JP2006507013A5 true JP2006507013A5 (enExample) 2008-07-03
JP4585968B2 JP4585968B2 (ja) 2010-11-24

Family

ID=31721472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005506130A Expired - Fee Related JP4585968B2 (ja) 2002-05-10 2003-05-12 ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法

Country Status (8)

Country Link
US (3) US20040091486A1 (enExample)
EP (1) EP1575509B1 (enExample)
JP (1) JP4585968B2 (enExample)
AT (1) ATE530577T1 (enExample)
AU (2) AU2003276832A1 (enExample)
CA (1) CA2485548A1 (enExample)
ES (1) ES2377720T3 (enExample)
WO (1) WO2004014292A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
JP2006501153A (ja) * 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション 診断及び治療用標的としての低分子量タンパク質チロシンホスファターゼ（ｌｍｗ−ｐｔｐ）
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US8012681B2 (en) 2003-05-13 2011-09-06 Novartis Vaccines And Diagnostics, Inc. Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
DE602005025459D1 (de) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
EP2275445A3 (en) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005295158A1 (en) * 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
CA2585671A1 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR101363252B1 (ko) 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
EP1968998A4 (en) * 2005-12-21 2010-01-27 Medimmune Llc AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
KR20100056438A (ko) * 2007-06-18 2010-05-27 메디뮨 엘엘씨 ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
TWI655210B (zh) 2010-12-08 2019-04-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
CN103857700A (zh) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
JP2016507555A (ja) * 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
CA2902505A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
FR3025717A1 (fr) * 2014-09-16 2016-03-18 Univ Lille Sciences Tech Utilisation conjointe d'un inhibiteur de trka et d'un inhibiteur de epha2 pour une utilisation dans le traitement de cancers
EP3221351B1 (en) 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
US10197563B2 (en) 2015-11-10 2019-02-05 New Jersey Institute Of Technology 3-D in vitro model for breast cancer dormancy
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US436782A (en) * 1890-09-23 Process of preparing carbonated beverages
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US952560A (en) * 1909-06-28 1910-03-22 Gewerkschaft Der Stein Kohlenzeche Mont Cenis Process of obtaining ammonium sulfate from gases.
US1131262A (en) * 1914-07-31 1915-03-09 Frank Orth Regenerator for furnaces.
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
CA2096417C (en) * 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
AU685765B2 (en) * 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
AU702522B2 (en) * 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
WO1999008696A1 (en) * 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
AU6784400A (en) * 1999-08-17 2001-03-13 Glaxo Group Limited Treatment of metastatic disease
DE60045075D1 (de) * 1999-08-17 2010-11-18 Purdue Research Foundation Anti-epha2 antikörper als krebsdiagnostikum
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
NZ521898A (en) * 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
AU9684601A (en) * 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
DE60239535D1 (de) * 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7250495B2 (en) * 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US7504211B2 (en) * 2002-08-27 2009-03-17 Bristol-Myers Squibb Company Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
JP2007526208A (ja) * 2003-04-11 2007-09-13 メディミューン，インコーポレーテッド 呼吸器の症状を治療又は予防する方法
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP2005538701A5 (enExample)
RU2627176C2 (ru) Новые модуляторы и способы их применения
US9388248B2 (en) Anti-CXCR4 antibodies and their use for the treatment of cancer
JP2005533493A5 (enExample)
US9249223B2 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
JP2022513053A (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
JP2008529497A5 (enExample)
JP2010523096A5 (enExample)
JP2008537673A5 (enExample)
JP2017538439A5 (enExample)
KR20180054492A (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
JP4088655B2 (ja) 抗ａ３３抗体
RU2006146666A (ru) Антитела и родственные молекулы, связывающиеся с белками psca
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
EP3137909A1 (en) Diagnostic anti-cd95l antibody
JP2020515286A5 (enExample)
US7074613B1 (en) Monoclonal antibody directed against cells of human renal cell carcinoma
AU2017277288B2 (en) Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
CN114933656A (zh) 抗cd123抗体及其应用
TWI919340B (zh) 抗體及其應用
WO2018202794A1 (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
CN121008043A (zh) Axl-gas6复合物的检测方法及在心肌梗死患者中的应用
CN121311503A (zh) 靶向itga2的抗体、其抗体药物缀合物以及用途
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
CN121794292A (zh) 抗体及其应用